HIT Consultant January 18, 2022
What You Should Know:
– Today, Sema4 (Nasdaq: SMFR), a health intelligence company, announced it has signed a definitive agreement to acquire GeneDx, a leader in genomic testing and analysis, at a purchase price representing approximately $623 million, strengthening its market-leading health intelligence and genomic screening offerings.
– The combined company is projected to deliver $350 million in pro forma 2022 revenue. In connection with the acquisition, Sema4 also completed a $200 million private placement from top-tier investors, including Pfizer.
Advanced Genomic Testing to Patients and Their Families
Founded in 2000, GeneDx’s premier rare disease diagnostic and exome sequencing services, and market-leading exome database, strengthen Traversa™, Sema4’s comprehensive genomic analysis platform for optimizing health screenings, as well as...
Today's Sponsors
Today's Sponsor